What conditions and goals does tirzepatide help with?

How does tirzepatide actually work in the body?

Most people have heard of GLP-1 medicines, but tirzepatide adds a second receptor into the mix. It activates both the GLP-1 and the GIP receptors, two pathways involved in appetite regulation and blood-sugar control. Stimulating them together slows the rate at which the stomach empties, reduces hunger signals reaching the brain, and improves the way the body handles glucose after meals.

The practical result is that most people find they feel fuller on less food and think about eating less often. That shift happens at a biological level, not through willpower alone. The full explanation of how tirzepatide works covers the receptor science in more depth if you want it.

It's also worth knowing that tirzepatide is a once-weekly injection, not a daily tablet. A pre-filled KwikPen is used subcutaneously, abdomen, thigh or upper arm. Treatment starts at 2.5mg, which exists to let the body adjust rather than to produce the main effect, and a prescriber guides any titration from there. The tirzepatide overview page covers the UK dose range and injection basics.

What does tirzepatide help with in terms of weight?

The weight-management licence covers adults with a BMI of 30 or above, or 27 and above where at least one weight-related health condition is present, such as high blood pressure, high cholesterol, prediabetes, type 2 diabetes, or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK clinical guidance.

In SURMOUNT-1, a large randomised trial published in the New England Journal of Medicine, participants using the 15mg maintenance dose lost an average of around 20–21% of their body weight over 72 weeks alongside a reduced-calorie diet and increased activity. That is a meaningful difference from previous options. A closer look at the evidence on tirzepatide and weight loss walks through the SURMOUNT findings in detail.

NICE recommends tirzepatide for NHS adults with a BMI of 35 or above alongside at least one weight-related condition, though private eligibility follows the licensed criteria above. BMI alone never tells the whole story; a prescriber considers your full picture before any approval.

Does tirzepatide help with anything beyond weight?

The question our prescribers hear fairly often is whether tirzepatide does anything for the conditions that tend to travel with excess weight. The honest answer is: the evidence is genuinely promising, though the primary UK licences are for weight management and type 2 diabetes specifically.

Across the SURMOUNT trials, participants commonly saw improvements in blood pressure, triglycerides and HDL cholesterol alongside weight reduction. There is a dedicated page on tirzepatide and cholesterol if that is your main concern. Reductions in liver fat have also been observed in trial data, which is relevant for people with non-alcoholic fatty liver disease, though tirzepatide does not currently hold a UK licence for that indication.

For type 2 diabetes, tirzepatide is licensed as a treatment in its own right, improving HbA1c and supporting weight loss simultaneously. If you have type 2 diabetes and are considering it for that reason, a prescriber at our clinical team can assess your full medication history, including any interactions to watch for, the medicines that need careful consideration alongside tirzepatide page is a useful read before your consultation.

What are the side effects worth knowing about?

Tirzepatide's side-effect profile is led by the gut. Nausea, diarrhoea, constipation, indigestion and fatigue are the most commonly reported effects, and they tend to be most noticeable in the first weeks of treatment or after a dose increase. For most people they settle.

There are rarer but more serious effects that need prompt medical attention. Severe, persistent stomach pain that spreads to the back (with or without vomiting) is a symptom of pancreatitis, which the MHRA highlighted in a Drug Safety Update in January 2026 as an infrequent but serious risk with GLP-1 medicines. Anyone on tirzepatide who experiences that symptom should seek urgent medical help rather than wait. Dehydration from prolonged vomiting or diarrhoea, and signs of an allergic reaction, are the other situations where you should not sit it out.

If you are using oral contraceptives, there is specific guidance: NHS advice recommends adding a non-oral method of contraception for the first four weeks of tirzepatide treatment and for four weeks after each dose increase, because tirzepatide may reduce how reliably the pill is absorbed. This is not a reason to avoid treatment, it is a reason to plan ahead with your prescriber. The Mounjaro support page covers practical questions like this.

Tirzepatide is not recommended during pregnancy, whilst breastfeeding, or for anyone trying to conceive. It is not licensed for under-18s. A full personal history review happens before any prescription is issued, that is not a formality, it is the point.

If you'd like to explore whether tirzepatide is appropriate for you, the first step is a free consultation with our prescribers. There is no obligation, no subscription, and your answers are reviewed by a named clinician the same day. Treatment pricing and what is included are laid out on the treatment overview page.